Last reviewed · How we verify
ASC42
ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation.
ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation. Used for Non-alcoholic steatohepatitis (NASH).
At a glance
| Generic name | ASC42 |
|---|---|
| Sponsor | Gannex Pharma Co., Ltd. |
| Drug class | FXR agonist |
| Target | FXR |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 1 |
Mechanism of action
FXR (Farnesoid X Receptor) activation by ASC42 leads to the regulation of genes involved in bile acid synthesis, transport, and metabolism, which can help reduce liver fat accumulation and inflammation, making it a potential treatment for non-alcoholic steatohepatitis (NASH).
Approved indications
- Non-alcoholic steatohepatitis (NASH)
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects (PHASE1)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects (PHASE1)
- Drug Interaction Study of ASC42 With Atorvastatin (PHASE1)
- Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis (PHASE2)
- Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV (PHASE2)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASC42 CI brief — competitive landscape report
- ASC42 updates RSS · CI watch RSS
- Gannex Pharma Co., Ltd. portfolio CI